(betaR)-beta,3-dihydroxy-N-methyl-L-tyrosine | 92843-37-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (betaR)-beta,3-dihydroxy-N-methyl-L-tyrosine
• 英文别名: (2S,3R)-3-(3,4-dihydroxyphenyl)-3-hydroxy-2-(methylamino)propanoic acid
• CAS: 92843-37-3
• 化学式: C₁₀H₁₃NO₅
• 分子量: 227.21
• InChiKey: RPXZFIAFSLMEJW-DTWKUNHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.7
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  110
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (2S,3R)-3-[3,4-bis(phenylmethoxy)phenyl]-3-hydroxy-2-(methylamino)propanoic acid 生成 (betaR)-beta,3-dihydroxy-N-methyl-L-tyrosine
  参考文献：
  名称：

  UMEZAWA, HAMAO;NAGATSU, TOSHIHARU;NARABAYASHI, HIROTARO;TAKEUCHI, TOMIO;I+

  摘要：

  DOI：

文献信息

• METHOD FOR PRODUCING THREO-3-(3,4-DIHYDROXYPHENYL)-L-SERINE
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP2450343A1

  公开（公告）日：2012-05-09

  The present invention provides a process for producing Droxidopa or a pharmaceutically acceptable salt thereof comprising a step of reacting threo-N-phthaloyl-3-(3,4-dihydroxyphenyl)-L-serine represented by the formula (1) with methylamine, whereby a process for producing threo-3-(3,4-dihydroxyphenyl)-L-serine (common name: Droxidopa), which is useful as an agent for treatment of peripheral orthostatic hypotension or an agent for treatment of Parkinson's disease, with high production efficiency and without requiring troublesome operations.

  本发明提供了一种生产屈昔多巴或其药学上可接受的盐的工艺，该工艺包括使式（1）所代表的硫代-N-邻苯二甲酰基-3-(3,4-二羟基苯基)-L-丝氨酸与甲胺反应的步骤，从而提供了一种生产硫代-3-(3,4-二羟基苯基)-L-丝氨酸（通用名称：屈昔多巴）的工艺：Droxidopa）的生产工艺，该产品可用于治疗外周性正位性低血压或帕金森病，生产效率高，无需繁琐的操作。
• UMEHDZAVA, XAMAO;NAGATSU, SYUNDZI;NARAXAYASI, XIROTARO;TAKEHUTI, TOMIO;IV+
  作者：UMEHDZAVA, XAMAO、NAGATSU, SYUNDZI、NARAXAYASI, XIROTARO、TAKEHUTI, TOMIO、IV+

  DOI：——

  日期：——
• PROCESS FOR THE PREPARATION OF DROXIDOPA
  申请人：Divi's Laboratories Limited

  公开号：US20170335357A1

  公开（公告）日：2017-11-23

  A novel process for the preparation of L-threo-dihydroxyphenylserine (Droxidopa) is described. It comprises of enantioselective hydrolysis of racemic (DL)-threo-N-acetyl-3-(3,4-methylenedioxyphenyl)-serine using commercially available L-amino acylase from Aspergillus sp. (EC 3.5.1.14) in the presence of cobalt ions, to obtain (L)-threo-3-(3,4-methylenedioxyphenyl)-serine followed by dealkylation to obtain Droxidopa. Protecting the amino group of (L)-threo-3-(3,4-methylenedioxyphenyl)-serine using either benzyloxycarbonyl or phthaloyl group before dealkylation followed by deprotection of the amino group results in obtaining Droxidopa in high yields and purity.